Johnson & Johnson (JNJ) Change in Inventory (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Inventory of $431.0 million for Q1 2026, up 836.96% sequentially from $46.0 million in Q4 2025, and up 195.21% YoY from $146.0 million in Q1 2025.
Johnson & Johnson (JNJ) Change in Inventory (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Change in Inventory data on file, last reported at $431.0 million in Q1 2026.
- Quarterly Change in Inventory rose 195.21% year-over-year to $431.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 87.37% YoY) and the FY2025 annual result came in at $1.5 billion, up 28.55% from the prior year.
- Change in Inventory improved to $431.0 million in Q1 2026 per JNJ's latest filing, from $46.0 million in the prior quarter.
- The five-year high for Change in Inventory was $1.3 billion in Q1 2023, with the low at -$124.0 million in Q4 2023.
- Average Change in Inventory over 5 years is $418.7 million, with a median of $391.0 million recorded in 2024.
- Year-over-year, Change in Inventory sank 109.19% in 2023 and soared 195.21% in 2026.
- Johnson & Johnson's Change in Inventory stood at $600.0 million in 2022, then sank by 120.67% to -$124.0 million in 2023, then jumped by 172.58% to $90.0 million in 2024, then sank by 48.89% to $46.0 million in 2025, then jumped by 836.96% to $431.0 million in 2026.
- Business Quant data shows JNJ's Change in Inventory at $431.0 million in Q1 2026, $46.0 million in Q4 2025, and $748.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 431.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 184.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -18.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 52.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -116.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 431.00 Mn |
| Mar 29, 2026 | 431.00 Mn |
| Dec 28, 2025 | 46.00 Mn |
| Dec 28, 2025 | 46.00 Mn |
| Sep 28, 2025 | 748.00 Mn |
| Sep 28, 2025 | 748.00 Mn |
| Jun 29, 2025 | 510.00 Mn |
| Jun 29, 2025 | 510.00 Mn |
| Mar 30, 2025 | 146.00 Mn |
| Mar 30, 2025 | 146.00 Mn |
| Dec 29, 2024 | 90.00 Mn |
| Dec 29, 2024 | 90.00 Mn |
| Sep 29, 2024 | 299.00 Mn |
| Sep 29, 2024 | 299.00 Mn |
| Jun 30, 2024 | 391.00 Mn |
| Jun 30, 2024 | 391.00 Mn |
| Mar 31, 2024 | 348.00 Mn |
| Mar 31, 2024 | 348.00 Mn |
| Dec 31, 2023 | -124.00 Mn |
| Dec 31, 2023 | -124.00 Mn |